An expanded access programme of Translarna (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)

Trial Profile

An expanded access programme of Translarna (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 21 Aug 2014

At a glance

  • Drugs Ataluren (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 21 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top